San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Longboard Pharmaceuticals is raising $56,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kevin Lind played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Longboard Pharmaceuticals

Welcome to Longboard Pharmaceuticals, a clinical-stage company leveraging over 20 years of proven GPCR discovery research to develop first- or best-in-class therapies with optimized pharmacology and pharmacokinetics to transform the lives of patients living with rare neurological diseases. Longboard Pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Longboard, formerly known as Arena Neuroscience, was a wholly-owned subsidiary of Arena Pharmaceuticals, Inc. until its launch in October 2020. Longboard’s compounds were discovered and evolved out of Arena’s validated world-class GPCR research engine.

To learn more about Longboard Pharmaceuticals, visit http://www.longboardpharma.com/

Contact:
Kevin Lind, Chief Executive Officer
619-592-9775
https://www.linkedin.com/in/kevin-lind-983b12106/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved